Abstract:Cerebrotendinous Xanthomatosis (CTX) is a lipid storage disease caused by recessively inherited pathogenic variants in (OMIM 213700). The classic clinical presentation includes infantile-onset chronic diarrhea, juvenile-onset bilateral cataracts, with development of tendon xanthomas and progressive neurological dysfunction. These multisystem clinical features typically appear in different decades of life often confounding diagnosis of CTX. Further complicating diagnosis is the generally held belief that the clinical presentation of CTX varies highly between individuals and even within families. CTX is a treatable disorder and treatment is most effective when started in the first two decades of life, rendering a particular urgency to diagnosis. In this study we bring a novel approach to detecting genotype phenotype associations in CTX. We conducted a systematic review of the literature to identify all functional analyses of pathogenic variants at the level of mRNA, protein and enzyme activity. We identified missense variants that result in complete loss of function (LOF) as well as missense variants that are have some partial function (hypomorphs). Next, we identified every CTX patient in the medical literature whose genotype and clinical phenotype were reported, and binned them according to functional genotype: LOF vs hypomorph. Analysis of these clinical, biochemical and molecular genetics data revealed a clear genotype phenotype association for CTX based on individuals who had two LOF variants vs two hypomorphs. The prevalence of each clinical feature was significantly higher in individuals with two LOF variants for every feature except tendon xanthoma and pyramidal signs. CTX had a detrimental effect on cognition for almost everyone with two LOF variants (96%), while tendon xanthomas were the most common feature in individuals with two hypomorphs (88%). We suspect this is due to ascertainment bias; individuals with a milder form of CTX may not get diagnosed with CTX unless they have this unusual hallmark of the disease. We studied the population genetics of the pathogenic alleles in gnomAD (N∼800,000). Estimated disease incidence based on carrier frequencies was consistent across the African/African American, Admixed American and European populations (1/308,000). However, no African/African American individuals have been reported in the medical literature as having CTX. Analyses of the pathogenic alleles in each population showed that the frequency of hypomorph pathogenic alleles was twice as high in African/African Americans (p=3.6E-4) vs Europeans (p=1.2E-4). Conversely, LOF alleles had a lower frequency in African/African Americans than in Europeans, p=6.1E-4 vs p=8.6E-4, respectively. By combining clinical, molecular, functional and populations genetics we uncovered a large health disparity in the diagnosis and treatment of CTX in African Americans and point to the milder clinical presentation of hypomorphs as an underlying component. The results of this study reveal specific opportunities for mitigating this disparity through recognition of the milder form of CTX as a clinical entity that is driven by hypomorph genetic alleles and broad adoption of biochemical testing that utilizes more sensitive biomarkers. Applying the framework and concepts leveraged in this study to the diagnosis of all monogenic disorders will likely result in improved diagnosis and health equity for the rare disease community.

Clinical Phenotype of a Rare Pathogenic Variant in STXBP1 Gene

Assessing the Landscape of STXBP1-related Disorders in 534 Individuals

STXBP1 encephalopathies: Clinical spectrum, disease mechanisms, and therapeutic strategies

Novel Splice Site Pathogenic Variant in STXBP1 Gene in a Child with Intellectual Disability, Epilepsy, and Autism Spectrum Disorder: A Case Report

Clinical spectrum of STX1B-related epileptic disorders

GABAergic/glycinergic and glutamatergic neurons mediate distinct neurodevelopmental phenotypes of STXBP1 encephalopathy

SPTAN1 Variants Likely Cause Autosomal Recessive Complicated Hereditary Spastic Paraplegia

Genotype and phenotype spectrum of 10 children with STXBP1 gene-related encephalopathy and epilepsy

A De Novo Splicing Mutation of STXBP1 in Epileptic Encephalopathy Associated with Hypomyelinating Leukodystrophy

Mutation in the STXBP1 Gene Associated with Early Onset West Syndrome: A Case Report and Literature Review

Two novel variants of the STXBP1 and CHRNB2 genes identified in a Chinese boy with refractory seizures and developmental delay

Studying ultra-rare variants in STX1A uncovers a novel neurodevelopmental disorder

Genotype-phenotype correlations of STXBP1 pathogenic variants and the treatment choices for STXBP1-related disorders in China

Reduced protein stability of 11 pathogenic missense STXBP1/MUNC18-1 variants and improved disease prediction

Reduced synaptic depression in human neurons carrying homozygous disease-causing STXBP1 variant L446F

Disease-linked mutations in Munc18-1 deplete synaptic Doc2

STXBP1: fast-forward to a brighter future - a patient organization perspective

SYN1 variant causes X-linked neurodevelopmental disorders: a case report of variable clinical phenotypes in siblings

Impaired neuronal activity and differential gene expression in STXBP1 encephalopathy patient iPSC-derived GABAergic neurons

Accelerating therapeutic development and clinical trial readiness for STXBP1 and SYNGAP1 disorders

Leveraging Clinical, Functional, Molecular and Population Genetic Data Reveals Genotype Phenotype Association and Health Disparity in a Monogenic Disorder, CTX